Baricitinib in Relapsing Giant Cell Arteritis

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 9, 2017

Primary Completion Date

April 12, 2021

Study Completion Date

April 12, 2021

Conditions

Arteritis, Giant Cell

Interventions

DRUG

Baricitinib

4 milligrams oral Baricitinib daily for 52 weeks

Trial Locations (1)

Mayo Clinic, Rochester

All Listed Sponsors

collaborator

Eli Lilly and Company

INDUSTRY

lead

Matthew J Koster

OTHER

NCT03026504 - Baricitinib in Relapsing Giant Cell Arteritis | Biotech Hunter | Biotech Hunter